A double blind, randomized, placebo controlled, two part, two session balanced, crossover study to evaluate visual changes in healthy male subjects aged 18 - 55 years after receiving: 1. at least 15 doses of 20 mg vardenafil, compared to placebo and 2. two doses of sildenafil, 200 mg compared to placebo.

Trial Profile

A double blind, randomized, placebo controlled, two part, two session balanced, crossover study to evaluate visual changes in healthy male subjects aged 18 - 55 years after receiving: 1. at least 15 doses of 20 mg vardenafil, compared to placebo and 2. two doses of sildenafil, 200 mg compared to placebo.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs Sildenafil; Vardenafil
  • Indications Erectile dysfunction
  • Focus Pharmacodynamics
  • Sponsors Bayer
  • Most Recent Events

    • 09 Mar 2009 Actual patient number (63) added as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Bayer HealthCare added as trial affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top